A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients with Nonsense Mutation Cystic Fibrosis
A study for patients with cystic fibrosis using study drug ataluren (PTC124)
Sponsor: PTC Therapeutics
Enrolling: Male and Female Patients
Study Length: 1 Years
IRB Number: AAAO2702
U.S. Govt. ID: NCT02139306
Contact: Eva Aquino: 212-305-4675 / ema2180@columbia.edu
Additional Study Information: The purpose of this study is to find out whether the study drug altaluren can help lung function and can reduce the symptoms associated with cystic fibrosis (CF), and decrease the number of hospitalizations and the use of antibiotics for CF-related lung infections. The study will also investigate whether the drug can help improve overall patient quality of life and is safe for children and adults to take as long-term treatment.
This study is closed
Emily DiMango, MD
Do You Qualify?
Do you have any known hypersensitivity to any of the ingredients of altaluren? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Eva Aquino